Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mondias strengthens its management structure

Mondias strengthens its management structure

Canada NewsWire

MONTREAL, May 8, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the appointment of Mr. André Rancourt as Executive Chairman, and of Mr. Derek Lindsay as Vice President, Corporate Development, effective immediately. Mr. Rancourt was previously Chairman of the Board.

Logo: Mondias Naturals (CNW Group/Mondias Natural Products Inc.)

"The appointment of Mr. Rancourt as Executive Chairman clearly strengthens the structure and depth of our management," said Jean-Philippe Gravel, Chief Executive Officer of Mondias. "Mr. Rancourt's wealth of expertise, vast network and involvement in day-to-day strategy and operations will greatly contribute to our expansion efforts."

"We are also pleased to have Mr. Lindsay join the Mondias team. His proven expertise in raising equity and financing projects, structuring creative strategic partnerships, increasing investor awareness and completing acquisitions will be an asset for Mondias as the Company embarks on its next growth phase," added Mr. Gravel.

Mr. Lindsay is a seasoned financial executive with extensive international experience in accelerating the growth of emerging companies. Over the course of his career, he has been instrumental in raising significant equity and debt financing, completing acquisitions and closing strategic partnerships. Mr. Lindsay holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.A. from Middlebury College, U.S.A.

Mr. Lindsay's responsibilities with Mondias include financing, investor relations and acquisition activities, as well as participating in the identification and assessment of new business opportunities, with the goal of accelerating the Company's growth.

The Company also announces that the board of directors has approved the granting of 650,000 stock options to directors, officers, consultants and employees under the Company's stock option plan. The exercise price of the options is $0.235 (the closing price of the shares on May 6, 2019). The options will vest in equal instalments over a three-year period and expire on May 6, 2029.  The options and the stock option plan are subject to shareholder approval at Mondias' annual and special shareholder meeting on June 10, 2019.

Pursuant to this stock option grant, the Company has a total of 3,600,408 stock options outstanding, which represents less than 6% of the Company's issued and outstanding common shares.

About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental Sciences.

For more information, visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.


SOURCE Mondias Natural Products Inc.

View original content to download multimedia:

Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569,; L. Derek Lindsay, Vice President, Corporate Development, 514-594-2372, dlindsay@mondias.caCopyright CNW Group 2019